Caliway Biopharmaceuticals stock: CBL-514 gets China trial clearance

Caliway Biopharmaceuticals announced on November 6 that China's Center for Drug Evaluation has authorized its CBL-0102 clinical study for CBL-514 to proceed. The company said the authorization from the Center for Drug Evaluation of the National Medical Products Administration came ahead of schedule.

China study moves toward enrollment

The trial is expected to begin enrolling participants in December 2026 and is planned for completion in the second quarter of 2027. Caliway expects clinical data shortly after completion, according to the company's announcement.

CBL-0102 is designed as a randomized, open-label, single-dose, parallel-group study involving approximately 30 healthy subjects at two sites in China. The program will assess ethnicity sensitivity, pharmacokinetics, safety and tolerability across different dose levels. The results could support later clinical development and regulatory submissions in China and other Asian markets.

Milestone adds a regional development leg

The China study is part of Caliway's broader development program for CBL-514, an investigational injectable candidate intended for localized subcutaneous fat reduction. The company says more than 544 subjects have participated in related clinical trials and that ten completed trials with finalized statistical reports met their primary and key secondary efficacy endpoints. Those company-reported outcomes do not establish regulatory approval or commercial availability.

For investors, the China authorization adds a defined regional development timetable, while enrollment and future clinical results remain important execution milestones. Caliway also said the study could strengthen its development and licensing strategy in Asia-Pacific.

For broader market context, follow current Taiwan TAIEX market reports.

More news and analyses are available on Caliway Biopharmaceuticals stock.